COSCIENS Net Working Capital from 2010 to 2026

CSCI Stock   2.10  0.06  2.78%   
COSCIENS Biopharma's Net Working Capital is increasing with slightly volatile movements from year to year. Net Working Capital is predicted to flatten to about 14.8 M. For the period between 2010 and 2026, COSCIENS Biopharma, Net Working Capital quarterly trend regression had mean deviation of  3,649,799 and range of 11.6 M. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
19.3 M
Current Value
14.8 M
Quarterly Volatility
4.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 99.3 K or Total Revenue of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.59. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Build AI portfolio with COSCIENS Stock
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

Latest COSCIENS Biopharma's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of COSCIENS Biopharma over the last few years. It is COSCIENS Biopharma's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

COSCIENS Net Working Capital Regression Statistics

Arithmetic Mean10,479,656
Geometric Mean9,798,032
Coefficient Of Variation40.99
Mean Deviation3,649,799
Median7,659,357
Standard Deviation4,295,310
Sample Variance18.4T
Range11.6M
R-Value0.79
Mean Square Error7.3T
R-Squared0.63
Significance0.0001
Slope674,539
Total Sum of Squares295.2T

COSCIENS Net Working Capital History

202614.8 M
202519.3 M
202416.8 M
202313.1 M
202218.5 M
202111.4 M

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's Net Working Capital, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Working Capital19.3 M14.8 M

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.54)
Revenue Per Share
2.996
Quarterly Revenue Growth
0.176
Return On Assets
(0.17)
Return On Equity
(1.13)
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.